Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches

Pîrlog, Radu; Şuşman, Sergiu; Iuga, Cristina; Florian, Ștefan Ioan

doi:10.3390/medicina55080412

Cited by 11 publications

(8 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, the diagnostic significance of detecting some proteins in body fluids for the diagnosis of glioma development has been shown [35,36,[60][61][62][63]. Among these proteins, the most representative are Vascular Endothelial Growth Factor and angiogenesis-associated proteins (FGF-b, IGFBP-2, EGF, and others), extracellular matrix proteins (TSP1/2, TNC, Cyr61/CCN1, OPN, etc.…”

Section: Proteinsmentioning

confidence: 99%

Diagnosis of Glioma Molecular Markers by Terahertz Technologies

et al. 2021

View full text Add to dashboard Cite

This review considers glioma molecular markers in brain tissues and body fluids, shows the pathways of their formation, and describes traditional methods of analysis. The most important optical properties of glioma markers in the terahertz (THz) frequency range are also presented. New metamaterial-based technologies for molecular marker detection at THz frequencies are discussed. A variety of machine learning methods, which allow the marker detection sensitivity and differentiation of healthy and tumor tissues to be improved with the aid of THz tools, are considered. The actual results on the application of THz techniques in the intraoperative diagnosis of brain gliomas are shown. THz technologies’ potential in molecular marker detection and defining the boundaries of the glioma’s tissue is discussed.

show abstract

Section: Proteinsmentioning

confidence: 99%

Diagnosis of Glioma Molecular Markers by Terahertz Technologies

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Proteomic studies of GBM have been extensively performed in several aspects, mainly to determine biomarkers 29 – 31 . Quantitative proteomics has become a powerful method for identifying valid predictive biomarkers for brain cancers 32 .…”

Section: Introductionmentioning

confidence: 99%

mTORC2 interactome and localization determine aggressiveness of high-grade glioma cells through association with gelsolin

Chantaravisoot

Wongkongkathep

Kalpongnukul

et al. 2023

Sci Rep

View full text Add to dashboard Cite

AbstractmTOR complex 2 (mTORC2) has been implicated as a key regulator of glioblastoma cell migration. However, the roles of mTORC2 in the migrational control process have not been entirely elucidated. Here, we elaborate that active mTORC2 is crucial for GBM cell motility. Inhibition of mTORC2 impaired cell movement and negatively affected microfilament and microtubule functions. We also aimed to characterize important players involved in the regulation of cell migration and other mTORC2-mediated cellular processes in GBM cells. Therefore, we quantitatively characterized the alteration of the mTORC2 interactome under selective conditions using affinity purification-mass spectrometry in glioblastoma. We demonstrated that changes in cell migration ability specifically altered mTORC2-associated proteins. GSN was identified as one of the most dynamic proteins. The mTORC2-GSN linkage was mostly highlighted in high-grade glioma cells, connecting functional mTORC2 to multiple proteins responsible for directional cell movement in GBM. Loss of GSN disconnected mTORC2 from numerous cytoskeletal proteins and affected the membrane localization of mTORC2. In addition, we reported 86 stable mTORC2-interacting proteins involved in diverse molecular functions, predominantly cytoskeletal remodeling, in GBM. Our findings might help expand future opportunities for predicting the highly migratory phenotype of brain cancers in clinical investigations.

show abstract

“…Proteomic studies of GBM have been extensively performed in several aspects, mainly to determine the biomarkers (Pirlog et al, 2019; Silantyev et al, 2019). Quantitative proteomics has become a powerful method for identifying valid predictive biomarkers for brain cancers (Miyauchi et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

mTORC2 Interactome and Localization Determine Aggressiveness of High-Grade Glioma Cells through Association with Gelsolin

Chantaravisoot

Wongkongkathep

Kalpongnukul

et al. 2022

Preprint

View full text Add to dashboard Cite

The mTOR complex 2 (mTORC2) has been implicated as a key regulator of glioblastoma cell migration. However, the roles of mTORC2 in the migrational control process have not been entirely elucidated. Here we elaborate that mTORC2 is crucial for GBM cell motility. Inhibition of mTORC2 impaired cell movement and negatively affected microfilaments and microtubules' functions. Later, we quantitatively characterized the mTORC2 interactome using affinity-purification mass spectrometry (AP-MS) in glioblastoma. We demonstrated that changes in cell migration ability alter mTORC2-associated proteins. These interacting proteins help determine the capability of glioma cell movement. Gelsolin (GSN) was identified as one of the most dynamic proteins in all criteria observed. We further discovered the GSN-mediated mTORC2 plasma membrane localization. Loss of GSN disconnected mTORC2 from numerous cytoskeletal proteins but did not affect mTORC2 integrity. In addition, we reported 86 stable mTORC2-interacting partners involved with diverse molecular functions, predominantly cytoskeletal remodeling in GBM.

show abstract

Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches

Cited by 11 publications

References 105 publications

Diagnosis of Glioma Molecular Markers by Terahertz Technologies

Diagnosis of Glioma Molecular Markers by Terahertz Technologies

mTORC2 interactome and localization determine aggressiveness of high-grade glioma cells through association with gelsolin

mTORC2 Interactome and Localization Determine Aggressiveness of High-Grade Glioma Cells through Association with Gelsolin

Contact Info

Product

Resources

About